JUN 08, 2016 02:00 PM PDT

Alteration of "Programmed Death Ligand" Promotes Cancer Metastasis

WRITTEN BY: Kara Marker
There’s a protein that signals the immune system not to kill certain cells. This action could be preventing autoimmune disease, or it could be harnessed by cancer cells to inhibit the immune system when it should be fighting back. A new study from Kyoto University in Japan uncovered genetic alterations to the protein that increase production in favor of growing tumors, and they plan to counteract these changes to prevent cancer growth.

Image credit: Kyoto University
 
The protein at the center of this study is called programmed-death ligand 1, or PD-L1. The genetic mutation that occurs and promotes cancer growth disrupts normal structure of the gene’s 3’ untranslated region of the gene the codes for the PD-L1 protein. The researchers plan to continue investigating these structural changes to understand how cancer cells can grow uncontrollably with the immune system inhibited by PD-L1 activity.
 
There are very effective treatment options using antibodies that target either PD-L1 or its receptor, PD-1, that exists on the surface of immune cells like T lymphocytes. However, these therapies are just as expensive as they are effective. In order to create treatment options that are both effective and affordable, the researchers from Kyoto University set out to identify cancer biomarkers to pinpoint which patients would respond especially well to immune checkpoint inhibitor drugs like PD-L1 targeting antibodies.
 
Of the 27 percent of patients with adult T cell leukemia or lymphoma who had genetic alterations of the 3’ untranslated region of the PD-L1 gene, the researchers used next-generation genetic sequencing data in attempt to identify the source of alteration. The researchers also sequenced data from over ten thousand samples from the Cancer Genome Atlas, finding similar alterations in other cancer types, including malignant lymphoma, stomach cancer, and cervical cancer.
 
The Cancer Genome Atlas is a collaboration between the National Cancer Institute and the National Human Genome Research Institute dedicated to providing comprehensive maps of key genomic changes in over 30 types of cancer.
 
The researchers were able to generate the same genetic alterations of the 3’ untranslated region of the PD-L1 gene in human and mouse cells using CRISPR-Cas9, a genome editing system using short palindromic repeats that target DNA based on sequence complementarity. Just like their previous findings, these cells had an elevated level of PD-L1 expression, and cancer cells were able to evade an immune attack.
 
On tap next for this research group is to test the structural genetic alteration as a genetic marker for cancer in a phase II clinical trial.
 
“Once we confirm the significance of these genetic alterations, it’ll be a game changer for immunotherapy in cancer,” said senior author of the study, Seishi Ogawa, PhD.
 

 
Sources: Kyoto University, New England Biolabs, Nature, Cancer Genome Atlas
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAY 08, 2018
Immunology
MAY 08, 2018
Nuclear Pore Complexes Vital for T Cell Survival
What’s happening on the molecular level that ensures protective T cells of the immune system will do their job? A new study from Sanford-Burnham Preb...
JUN 13, 2018
Health & Medicine
JUN 13, 2018
Insurance Denials Prevent Patients From Getting Hep C Medication
Some ads are running on television and in major magazines about drugs for hepatitis C, known as Hep C or HCV. Available in the United States since 2014, th...
JUL 04, 2018
Drug Discovery
JUL 04, 2018
Increased Dose of Drug 'Rifampin' Effective in Eliminating Tuberculosis Bacterium
According to a randomized controlled trial, a TB drug by the name ‘Rifampin’ was seen to effectively kill TB bacteria in sputum cultures when a...
JUL 11, 2018
Immunology
JUL 11, 2018
The Power of Seal Serum
Unlike humans, seals remain uninjured despite repeated deep dives to hunt. Scientists have shown that serum from seals blood provides anti-inflammatory properties that lower immune response....
JUL 15, 2018
Immunology
JUL 15, 2018
Enzyme Pathway Mediates Immune Response to Chagas Disease
The enzyme, PI3Kγ, regulates the immune response to T. cruzi, the cause of Chagas Disease. Manipulation of this enzyme may lead to better treatment of T. cruzi....
SEP 14, 2018
Immunology
SEP 14, 2018
Zika Strong Arms the Immune System
Zika Virus manipulates the genetic makeup of immune cells called macrophages....
Loading Comments...